Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ONCS > SEC Filings for ONCS > Form 8-K on 28-Nov-2012All Recent SEC Filings

Show all filings for ONCOSEC MEDICAL INC



Other Events

Item 8.01Other Events.

Effective November 26, 2012, Adil Daud, M.D., Shailender Bhatia, M.D., and Weiyun Ai, M.D. transferred their rights under the Investigational New Drug (IND) program for the use of ImmunoPulse in melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma to OncoSec Medical Incorporated (the "Company"). The transfer of these INDs permits the Company to assume exclusive sponsorship for ongoing and future clinical trials involving ImmunoPulse for the treatment of melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. Previously, clinical trials involving ImmunoPulse have been investigator-sponsored.

  Add ONCS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ONCS - All Recent SEC Filings
Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.